Bio Honey In 2025: The Pilot Worked, But The Real Proof Has Not Started Yet

Getting To Know The Company

At first glance, Bio Honey looks like a food-tech story that made real progress in 2025. The industrial pilot succeeded, the company raised capital, net loss narrowed, and the annual report already talks about commercial production and expansion toward the US market. That is only a partial reading. What really changed is not that the company became commercial, but that the bottleneck moved. In prior years the key question was whether cultured honey could be produced outside the lab. Now the key question is whether that capability can be turned into customers, approvals, and revenue before the cash balance starts shrinking again.

That is why Bio Honey should be read less like a food company and more like a pre-revenue commercialization story. By the end of 2025 the company had completed development of six cultured-honey products, added a low-carb keto-oriented honey product, completed a successful pilot with a food plant in northern Israel, and signed with another plant in central Israel for commercial production. At the same time, the same report still says the company has no revenue, no customers, and no order backlog. In other words, industrial feasibility is now much more tangible, but demand has not yet been proven.

What is working right now? First, the operating route looks more practical than before. The company is no longer speaking mainly about building its own plant as a heavy-capex project. Instead, it is leaning on existing plants for production, packaging, kosher certification, and regulatory support. Second, the cash position now looks very different: cash and cash equivalents jumped to about NIS 9.46 million at year-end 2025 from just NIS 421 thousand a year earlier, and the balance sheet also includes a financial asset measured at fair value of about NIS 1.23 million. Third, the product story is broader than one cultured-honey line. The company is trying to build adjacent commercial angles through keto honey and spicy honey.

What is still missing for the thesis to become cleaner? Three things are missing: a first customer, a regulatory path that moves from intention to execution, and proof that cash burn will not rise sharply again once the company shifts from preparation into routine production. That is exactly why 2026 looks less like a breakout year and more like a proof year. If the company reaches a first sale or signs a binding commercial agreement, the market reading can change quickly. If a few more quarters pass and the picture is still zero revenue with elevated overhead, the market will go back to reading the story as a development vehicle rather than a business.

The equity screen matters too. As of April 6, 2026, market cap stood at roughly NIS 16 million. This is still a clear micro-cap. The market is not valuing Bio Honey like a growing food company. It is valuing it mainly as a larger cash balance plus an option on commercialization. Put differently, the market does not need another flavor right now, it needs another proof point.

That chart highlights how much of Bio Honey's balance sheet is really a cash balance rather than a commercial operating base. Most of the assets sit in cash, and only a small slice reflects physical infrastructure. That is useful if the goal is flexibility, but it also underlines that value still depends on what the company can build from here, not on what already exists.

Events And Triggers

The move from lab work to plant-based production is real

The most important trigger in 2025 is not the capital raise. It is the reported move from lab production to industrial production. The company says the pilot with a food plant in northern Israel ended successfully on December 30, 2025, and that the pilot marked a successful transition from lab-scale production to industrial production. This is not cosmetic. As long as Bio Honey was only a company that could show a molecule, the bullish case rested mostly on promise. Once the company says it can produce at commercial quantities using standard industrial means, the focus shifts to a very different question: if it can make the product, who will buy it.

That step is reinforced by the agreement with a second plant in central Israel. The central plant is meant to provide not only manufacturing and packaging, but also regulatory and kosher support. In that sense the company is trying to take a shortcut. Instead of building its own facility, it is trying to lean on existing infrastructure, save capex, and move faster toward a sellable product. That is economically sensible, but it does not eliminate risk. It replaces facility-build risk with partner-execution risk, regulatory timing risk, and the challenge of managing commercialization with very limited internal resources.

The capital raise bought time and reset the managerial frame

On May 29, 2025 the company completed a capital raise of about NIS 9.1 million through the issuance of 6.5 million ordinary shares and 6.5 million Series 1 warrants. This is the balance-sheet turning point of the year. Without it, Bio Honey would have entered 2026 with a very thin cash cushion. With it, the balance sheet changed, equity rose to NIS 11.06 million, and the company gained real runway.

But the raise means more than that. It came after the late-2024 change of control to Ari Stiematzky, and alongside the installation of a permanent CEO, Yaakov Lekser. In other words, 2025 was not only a year of operating progress. It was also a year of managerial reframing. The company moved from a phase where the main question was immediate funding survival to one where management is being judged on two very concrete outputs: first sales and continued access to capital.

That signal also appears in the CEO incentive structure. He is entitled to a bonus if honey-product sales exceed $1 million within 24 months of the start of his term, and another bonus if more than NIS 5 million of capital is raised in a year. That is not a side detail. It tells you that at board level the real KPI for the coming years is not profitability. It is first revenue and continued financing capacity. Between the lines, that is an admission that the company is still in a bridge phase.

Wilk helped earnings, not core commercialization

In October 2025 Bio Honey invested NIS 500 thousand in Wilk Technologies. By year-end the fair value of that holding stood at about NIS 1.228 million, which produced about NIS 728 thousand of finance income. It is easy to see why management likes this move. It creates optionality for future cooperation in alternative food, and it also lifts reported earnings.

But it has to be read correctly. This is not a core business engine. It is a financial investment that lifted the finance line, not proof that cultured honey is selling. So anyone who sees the lower net loss and concludes that commercial execution materially improved is missing the picture. A meaningful part of the improvement came from deposit interest and fair-value gains, not from customer revenue.

This chart captures the 2025 paradox well. Operating loss improved, but the real swing between the 2024 and 2025 bottom line sits in the finance line. So the right read is not "the company moved onto better economics." The right read is "the company entered the year with more cash and with finance income that made the bottom line look cleaner."

Efficiency, Profitability And Competition

Net loss improved, but the ongoing cost base actually rose

The headline figure in the report is the drop in net loss from about NIS 5.95 million in 2024 to about NIS 3.91 million in 2025. It is tempting to read that as efficiency. In reality, the story is not that clean. If you look at operating loss before other expenses, the picture is less flattering: in 2024 that figure was about NIS 4.59 million, while in 2025 it rose to about NIS 4.87 million. In other words, beneath the cleaner headline loss, the recurring operating cost base actually worsened.

Why? Because R&D expense fell from NIS 2.72 million to NIS 1.70 million, mainly after the former VP of R&D left in mid-2025, but selling, general, and administrative expense jumped from NIS 1.87 million to NIS 3.17 million. The biggest swing inside that line was salaries and related payroll expense, which rose from NIS 155 thousand to NIS 1.77 million. Put simply, the company did not suddenly become cheaper, it shifted weight from the lab budget into management and commercialization overhead.

That is not automatically a problem. For a pre-revenue company moving from development toward commercialization, it is natural to redirect resources toward management, regulation, marketing, and partnerships. The problem starts when those new costs still have no first sale behind them. That is why 2025 shows direction, but still does not show unit economics.

What did improve operationally

To the company's credit, the report is no longer built only on vision. Bio Honey says it has completed development of six cultured-honey flavors, successfully completed the keto honey product, added spicy honey, and holds raw-material inventory sufficient for production of several tons of cultured honey. It is also working with several suppliers in order to avoid reliance on a single source. These are not sales numbers, but they do point to a much better operating-readiness position than in prior periods.

There is also progress in intellectual property. The company has two registered patents and six additional patent applications. That gives it a layer of protection, especially in a market that is still immature and where the main competitors referenced by the company are largely private. But this point also needs precision: a patent protects capability, not demand. It can strengthen the story, but it does not replace a commercial proof point.

What remains unproven

The main weakness of 2025 is that every hard commercial layer is still empty. There is no revenue. There are no customers. There is no order backlog. There is no established marketing and distribution system. There is a non-binding memorandum of understanding with Yogen Fruz, a global chain with more than 1,400 locations, but even at the end of 2025 the parties were still "examining" the cooperation and looking at US manufacturing options. The identity of that partner matters, because it shows the company is thinking correctly about route to market and distribution. But the more important word is still non-binding.

That is also why the competitive lens has to be framed properly. Bio Honey is not yet competing for share. It is competing to reach the commercial starting line before others do. If it has an advantage today, it is not brand or distribution. It is a mix of IP, technical progress, and the use of existing manufacturing sites to shorten time and reduce capital needs. That is a potential advantage, not a proven one.

This chart highlights another non-obvious point. The decline in R&D did not come from a breakthrough that suddenly made the technology cheaper. It came mainly through lower payroll and the disappearance of heavier depreciation after the company exited its old lab setup and sold part of its equipment. The expense reduction is real, but it does not mean the technology itself suddenly became light.

Cash Flow, Debt And Capital Structure

The right cash lens here is all-in cash flexibility

For Bio Honey there is no real value in talking about normalized or maintenance cash generation. There is no recurring business yet to normalize. The right lens is all-in cash flexibility, meaning how much cash remained after the period's actual uses of cash. On that basis, 2025 was a strong year. The company started the year with NIS 421 thousand of cash, used NIS 3.91 million in operating activities, invested NIS 500 thousand in Wilk and another NIS 11 thousand in fixed assets, but received NIS 9.08 million from financing activities and released NIS 4.38 million from deposits. The result was a year-end cash balance of NIS 9.46 million.

That means the cash balance did not grow because operations produced money. It grew because the capital markets funded the transition period. That is a critical distinction. If you look only at the year-end balance, you may get the sense of a strong balance sheet. If you look at the cash bridge, you understand that this is runway strength, not business-model strength.

The bridge also explains why lower accounting loss did not translate into meaningfully lower cash burn. Cash used in operating activities was NIS 3.91 million in 2025, almost unchanged from NIS 3.83 million in 2024. In other words, the accounting looks better, the cash burn did not get worse, but it also did not really get better.

The balance sheet is relatively strong, but the strength is financial rather than operational

At the end of 2025 Bio Honey had NIS 11.06 million of current assets, NIS 12.12 million of total assets, and NIS 11.06 million of equity. Total liabilities were only NIS 1.06 million, including NIS 546 thousand of lease liabilities. There is no heavy bank debt here, no covenant pressure, and no legal proceedings hanging over the company. That is a real advantage, especially for a company at this stage.

But the advantage needs to be kept in proportion. The cash balance looks comfortable, and the financial statement note explicitly says the cash position should support the next 12 months of activity. Arithmetically, if one extrapolates the 2025 cash burn on its own, it could appear to cover more than one year. Still, the company's own framing is more useful: once production, regulation, marketing, and distribution start moving together, spending can rise again. Anyone translating year-end cash directly into a fixed number of years of life is probably missing the transition stage the company is now entering.

This chart sharpens the way the market is reading the story. Market cap is already above the cash balance, but it is still not pricing a large premium for a proven commercial business. The market is assigning some value to the option, not only to the cash, but it is still demanding a heavy discount as long as revenue has not arrived.

Capital, control, and dilution

Bio Honey's capital structure tells a two-sided story. On one hand, it shows there is a controlling shareholder willing to fund the company, and that matters a lot for a small company at this stage. On the other hand, it also makes clear that the main financing route remains the equity market. At the report date Ari Stiematzky held 66.16% of the issued and paid-up share capital and also participated in the rights issue. That creates a control anchor and a funding backstop, but it also means common shareholders are likely to keep living with material dilution risk if commercialization takes longer than hoped.

Outlook

Finding one: industrial production proof is already here, but demand proof has not started yet.

Finding two: the better 2025 bottom line is driven more by finance income and interest than by commercialization.

Finding three: the hosted-manufacturing model materially reduces capex risk, but it does not solve customer, distribution, or regulatory risk.

Finding four: 2026 looks like a proof year. Even the company's own roadmap is framed around commercial production, regulatory completion, and sales initiation, not around profitability.

This is a proof year, not a breakout year

The company presents relatively ambitious 2026 goals: start routine commercial production, complete regulatory requirements in the US and Israel, and begin sales in the US market for cultured honey. For the keto honey product, the goal is industrial scale-up, US regulatory completion, and commercial launch. The logic is understandable, but it has to be read as a plan rather than hard guidance. The report still contains no customer, no order, and no binding commercial agreement that would anchor those goals.

That is why 2026 is not a breakout year. It is a test year. If the company shows a first commercial agreement, first revenue, or concrete regulatory progress, the market can start reading it as a commercialization name. If it ends 2026 with more pilots, more intentions, and still zero revenue, the conclusion will be that the operating path improved but the business path has not opened yet.

What management is signaling without saying it directly

There are several useful signals in the report. The first is the Yogen Fruz memorandum of understanding. The fact that the company continues to examine US manufacturing options together with that partner says management understands that the issue is not only how to produce, but how to enter a market with a partner that can turn product into shelf presence. The identity of Yogen Fruz matters because it is a broad international franchise platform. The fact that the arrangement is still not binding matters just as much.

The second signal is embedded in the language around cash. In the business section, the company says the cash balance is sufficient to execute all known business plans and R&D plans as of the report date. In the accounting note, the language is more conservative and speaks about 12 months. That is not an accounting contradiction, but it is an important tonal difference: at the business-messaging level management wants to project confidence, while the accounting framing remains careful.

The third signal is in the CEO incentive structure. A company that rewards management for first sales above $1 million within 24 months and for capital raises above NIS 5 million is essentially telling the market what really matters. Not gross margin, not EBITDA, not even profitability, but the move from promise to revenue and the preservation of financing access.

What has to happen over the next 2 to 4 quarters

The market's checklist is actually simple here:

What really matters now is not another product announcement. The company has already shown it can broaden the menu. The market will now wait to see whether anyone is willing to pay.

Risks

The central risk remains commercialization without hard anchors

The biggest risk is exactly where the numbers say it is: there is no revenue, no customer base, and no backlog. As long as that remains true, every operating milestone is still an intermediate step. The successful pilot matters, but it is not a substitute for a commercial signature.

Regulation, food quality, and production execution

The company will need to satisfy regulatory requirements in Israel and the US, rely on manufacturing partners that can provide not only production but also kosher certification, packaging, and standards compliance, and maintain consistent product quality. The company itself lists the risk that approvals may be delayed, may not be granted, or may arrive on harsher terms than expected. For a company with no revenue, every such delay costs both time and cash.

Financing and dilution remain structural parts of the story

The year-end cash balance is far stronger than it was a year earlier, but the company explicitly says that even if it meets its goals, it may still need additional capital raises before permanent positive cash flow is generated from product sales. That line matters. It means financing risk did not disappear, it was pushed out. Any delay in commercialization can quickly bring dilution back to the center of the story.

Execution bandwidth is limited

The company formally says it has no material dependence on any officer or employee. Economically, with only four employees and service providers in total, and only two people in the R&D and regulation layer, it is hard to argue there is a deep bench. That does not mean the company cannot succeed. It does mean that any departure, delay, or need to build production, regulation, marketing, and distribution in parallel could weigh heavily.

IP and competitive risk

Two registered patents and six additional applications are an important base, but they are far from a closed moat. The company itself says it cannot see competitors clearly because most of them are private, and there is no certainty all patent applications will mature into granted protection. At this stage, the protection exists, but the market certainty does not.

There are also mitigating points. There is no meaningful bank debt, no ongoing legal proceeding, there is a financially involved controlling shareholder, and the production route appears less capital-intensive than it once looked. So the risk here is high, but not chaotic. It is highly specific: can the company turn readiness into revenue.

---

Conclusions

Bio Honey ended 2025 in a better place than where it started the year. It has real cash, it has a successful industrial pilot, it has a less capex-heavy production route, and it has a broader product set. But it still has not crossed the line that turns a development company into a commercial one. As long as there is no revenue, no customer base, and no backlog, the core story remains an option on what has not yet happened.

Current thesis: Bio Honey bought time in 2025 and moved forward on production, but the missing proof is demand rather than lab capability.
What changed: the bottleneck shifted from the technical question to the commercial and regulatory question.
Counter thesis: if the hosted-manufacturing model truly works, first sales could arrive faster than expected and change the market reading quickly.
What could change the market's interpretation in the short to medium term: a binding commercial agreement, first revenue, or clear regulatory progress.
Why this matters: in a micro-cap like this, the gap between a successful pilot and a paying customer is almost the entire story.

Over the next 2 to 4 quarters the test is actually simple. If Bio Honey shows a first sale, a first customer, or a binding agreement that connects production to demand, then 2025 will look in hindsight like a successful bridge year. If not, 2025 will be remembered as the year in which the company proved it can produce, but still did not prove that anyone is ready to buy.